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~ Fat Infiltrates In Endomyocardlal Biopsies Lack 
Spealflclty for the Diagnosis of Right Ventrlcular 
Oysplasla 
A, Burke, E, Arbtmtlnl, B, dot Belle, P, Morblnl, G, Spocchtn, R, Virmanl, 
It~tltuto Anrffoml~l PatoIOglca, P~lvln, italy: And the Armed Forces Institute of 
Pathology, Wa,~hlogton, OC, USA 
Baokground; It h~s boon ~toted that fat Infiltration -,3,21% in ondomyoo~rdtnl 
biops o~ (EMB) i~ 91,5% spoctflo for the diagnosis of right ventfl¢ttlnr dy~ptn- 
~t~1 (Aogolinl ot at, tat, J CaM/el, tgg341', ~40, However, the fmquenw ~nd 
oRtot,~ { fR! Infiltrates in normal prttionl~ nnd pt~tlonts with dll~ted o,rdiomy. 
op~tny (DCM) has not boon o~tonslvoly studied 
Mothoc/~; EMBs from 30g oonsoguflvo normal head donors (moan 1,4 :t 
0,6 biopsy fragments) oed 100 EMB~;! t"om p~tlont~ with idiopathto dilated 
o,~rdlomyopathy (moan ~,0 ~ f,1 fragment,) wore evaluated, The % f~t 
infiltration determined morphomotrte~lly, 
R¢~ulf~: FP.t wa~ present In 69/421~ biopBy tragmonl~ (16%) in p~tionfs 
wtlh DCM end 32/425 (B%) of donor biopsy fragments (p ~ 0,001, In biopsies 
with fat infiltration, the moan % fat infiltration was 2B ~ ~6% in patients with 
DCM and IB ~ t3% in danom (p ,~ 0,0P., Patlont~ with, 1 biopsy were mare 
IiWoIv to h~vo f~l thnn those with only f biopsy (~5% v¢~, 8%, p .  0,00f, 
Overall, the mann % f~f (nllltr~lion was 4,5% tn pntiont~ with DCM and 1 ,~,% 
in danom, bgt woo not normally dlstrlb~g~d, 
Cnncht~ion: Fat infiltrates are pro~ont in up to 25% el EMBs, may be ex. 
tenslva, nnd, when pm~ent, u~ually e~eood 5%, They am more common and 
e~en~lvo In DCM than normal controls, and am not indic~ttivo inthemselves 
el fight vonfrlcuh~r dy~pl,~t~, 
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8 • 1 •  Effects of Pentoxltyillne on Left Ventrlcular 
Performance In Patients With Idiopathic Dilated 
Csrdlomyopathy 
K, Sliwa, e, ~kudickv, G, Candy, T, Wisenbaugh, P, Sareli. Department of 
C~rdiotogy, Bnmgwanafh H~pih11. Univemity of the Wltwatemrand, 
Joh~lnnosbu~, South Air/ca 
Background: increased plasma levels of tumor necrosis tactor.~r (TNF-.) 
have been repealed in patients (pts) wltl~ heart failure. Pontoxttylhne, a xan- 
thine denved agent has boon sl~own to suppress or reduce the produetlon of 
TNF~, 
Mefhoc~; prospective, double blind, randomized, placebo controlled triel, 
~n which 28 pts with idiopathic dilated cardtomyopathy were randomized 
to pentox~lyllino 400 mg TDS or placebo. Clinical, echocardiographtc and 
radlonuclido evaluation wore pedorrned af baseline and after 6 months of 
treatment. 
Results: there was a significant improvement in tunetional capacity with 
pentoxilyllino (2.7 ~t 0.5 to 1.2 ~ 0,4, p < 0.00001 ), This was associated with 
a significant increment in election traction (22.3% to 38.7%, p = 0.00007) and 
prolongation o1 the E wave deceleration time (133 ,t 56 to 176 ~. 65 msec, p 
= 0.03). No significant changes wore observed in the placebo group TNF-. 
plasma levers significantly declined w~th pentoxifylline (6.5 ;~ 3 te 2.1 ~t~ 1 
pg/mt, p= 0.001). 
Conclusions: these results suggest that treatment with pentoxifylline is 
associated with a significant improvement ot symptoms and parameters of 
left ventricular systolic and diastolic performance in pts with idiopathic dilated 
cardiomyopathy. 
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~ Irbesartan Compared With Llslnoprll in Patient;  With 
Mild to Moderate Heart Failure 
N. Vilay, I.A. Alhaddad, D. Marly Denny, D. Ruff, M. Yasin, L. Yellen, 
S. Lwer, C. Bryson, C.-S. Lin, R.A. Wolf. Irbesartan Heart Failur~ Group: 
Wes,em Ca,diology Associates, Denver, CO, USA 
This pilot study compared the efficacy and safety of irbesadan (IRBE, 
BMS/Sanofi) with lisinopril (LIS). 134 patients (pts) with symptomatic heart 
failure (HF, NYHA Class II or III) and left ventricular ejection fraction (LVEF) 
~,10% were entered. Prior to entry, pts had received stable doses of diuretics 
(~4 d) and and angiotensin converting enzyme inhibitors (ACE-Is) (~_6 wks). 
Open-label ACE-I therapy was stopped when pts were randomized to IRBE 
37.5 mg QD (n = 66) or LIS 5 mg QD (n = 68), (tittered to 150 mg and 20 me, 
respectively), 12-week efficacy variables Included changes from baseline in 
Modified Naughton exorclso tolerance test (ETT), LVEF, and oardtofhoracie 
ratio (CTR), Baseline domogrephics wore comparable (moan age: 66 ym, 
LVEF: 27%, CTR: 0,54. and 73% and 2~.  of pta had NYHA Class II and III 
HF, mspoctlvoly), 
Err (aec) modinn chnng~ ~.VEF (onit~) moan change CTR (units) mean ch~t~ 
IRBE 7~,5; 7-t3~' 1 90 (015.3,64) --001 (-0,0~0,00) 
LI~ 65,0; 7-t24' 0~1 f 0 fi5-~,37) ~00t (- 003-~'~,01) 
RBth~75th quantlloB: vnf|m~ in 0 represent 95% confidence timit~ 
IRBE and LtS h~d Bimilar lotorBbility pmfile~, ilCtgding the inccdenco f 
worsening HF nnd seriooB adverse events. Both dntgs showed coreparab!e 
offi(~y end stmilar clinical outcomo~ tn pfs with mttd40.moderafo HF. 
Cpnct¢t,,,on: I~bostt~n was well tolerated when substituted for ACE-I in pts 
with chronic HF 
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~3- ]  Compelrlson of the Long-term Effecle of Can/ed!!o! 
and Amlodsmne On Le!t Ven~l¢mlar Function in 
Patients With Dilated (:a~!iomyopathy 
U,K, Mu0IIor, M. Wells, D Skudicky, P Sam!i. Elara~,(ar~lth Hose#el, 
Johannesburg, South Atnca 
In patients with severn heart faih!re the addition ot cawedd01 to diuretics, 
digoxin and ACE-inhibitor therapy has resulted in in a signilicant improve- 
ment ef left vontflcular function and a consequent rnductton in moctatity. 
Although t,als el amtodarono in patients with congeshve head failure have 
produced discordant results with regard to effects on survival, most stud- 
ies hav~ repo~nd a significant nse in left venmcufar ejection fraction during 
Iong-tem~ therapy. Tho present study was undertaken to directly compare the 
effect on left vontficutar function el the 2 dregs: 37 portents with ichopathic 
dilated cardiomyopathy (IDCMO) who remained in NYHA functional class It 
despite 6 months of treatment with diuretics, digoxtn and an ACE-inhibdo¢ 
(trandolaprit 4 mg daily or onalapnl t0 mg bd) were prospectively randem~d 
to receive either amiodarone 200 mg daily or canredtloi 25 mg bd in nddlren 
te their other medication. The ochocardiographtc left ventncular dimensions 
at end-diastole (EDD), end.systole (ESD), fractional shortening |FS), and 
radionuclido ejection fraction (EF) at randomization (O) and after 6 months 
of treatment are shown in the table. There were no significant differences m 
age or sex composition in the 2 groups and no death or hosptial admission 
occurred during the randomization prated. 
Cawechtot (n : 18) Amloda~one [n: 191 
O 6 month p e 6 month p 
Ago 51 7.* 97y 4B5,~ 11 ry 
EDD 66::;0.95crn 631086cm NS 63~085cm 62~:093crn NS 
ESD 57 ~ t.lcrn 52~ 11cm 0or 56~: tOcm 51111cm oat 
FS 13 1 ~ 52% 180 ~ 7 3% 0.03 13.2 ± 70% 173 ±: 7.8% 002 
EF 283 t 105% 348 t 14.5% 001 25.9 :t 10.7% 34.7 ." 139% OOt 
There were no significant differences between the two study groups at the 
time of randomisation or alter 6 months of treatment (both absolute values 
and percentage change). 
Conclusion: The addition of either carvedtlot or amiodarone to standard 
antifailure treatment in patients with IDCMO significantly improved left ven- 
tricular performance, but with neither agent proving superior. 
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[ '~  Early Weight Gain Intervention Requires Drugs Less 
to Decrease Heart Failure Re-admissions 
M. Bondmass, N. Bolger, G. Castro, B. Avitall. University of Illinois at 
Chicago. USA 
Background: Hypervolemia is a challenging clinical problem in the manage- 
ment of heart failure. The timing of interventions following weight gain may 
influence the type of therapy used and affect hospital readmission rates. 
Methods: Following a head failure admission, 64 patients (NYHA class 
Ill-IV, rn~ -,n age 61 .L 13, 67% female, 63% African American), used a home 
modem-type monitor for two months. Weight, heart rate, blood pressure, and 
oxygen saturation were transmitted aily. Patients were telemanaged utilizing 
treatment protocols consistent with current heart failure guidelines. Treatment 
protocols, for all variables, were equivalent with the exception of weight 
increase interventions. Pmtecol one (n = 34) dictated phone assessment, 
patient education, and/or diuretic changes at >__5 pound increases. Protocol 
two (n = 30) required phone assessment, patient education, and/or diuretic 
changes at increases of 2 to 4 pounds. All patients were instructed to weigh 
